MS: Treatment did not boost protective cells after Lemtrada

Credibility

Interest

Share:1 min read

Key Takeaway

A low-dose immune treatment did not increase protective immune cells in people with relapsing MS who had previously received Lemtrada.

What They Found

The study tested whether a low dose of an immune signal could increase cells that help prevent immune attacks. In people treated with alemtuzumab (Lemtrada), these protective cells did not increase. Lab tests showed that other immune cells became more sensitive to the signal after Lemtrada treatment. In mice, the signal favored protective cells only when given later after treatment. The researchers concluded that the low-dose treatment alone was not a useful way to increase protective cells after Lemtrada.

Who Should Care and Why

The human study involved people with relapsing MS who had received Lemtrada more than six months earlier. It focused on cells that help keep the immune system from attacking the body. Such attacks can occur after Lemtrada treatment. Researchers also studied cells in the lab and mice given a treatment like Lemtrada. The findings concern an approach to increasing protective cells, not an improvement in MS symptoms.

Important Considerations

You should know this was an open-label study, meaning participants and researchers knew which treatment was given. The abstract does not state how many people took part. It does not show whether the low-dose treatment prevents immune problems after Lemtrada.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Early Research

Article Topics:

T-regulatory cellsautoimmunityinterleukin-2multiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News